More on compulsory registration of clinical trials: GSK has created useful register

doi:10.1136/bmj.330.7489.479-b

BMJ 2005;330:479-480 (26 February), doi:10.1136/bmj.330.7489.479-b

Letter

GSK has created useful register

The first 150 words of the full text of this article appear below.

EDITOR—The editorial by Abbasi and letters in responseillustrate the considerable interest in the registration ofclinical trials.^1
2 As a pharmaceutical company that has createda register to communicate the results of clinical trials ofour marketed products, GlaxoSmithKline would like to bring toyour attention the decisions we have taken to make our registerworthwhile and meaningful to the medical profession and otherswith an interest in clinical research.

The GSK Clinical Trial Register is comprehensive: it will includethe results from all GSK sponsored clinical trials (phases I-IV)of marketed medicines conducted anywhere in the world. The resultsinclude primary and secondary efficacy end points defined intrial protocols, and a summary of adverse events beyond whatis traditionally reported in publications. This informationis reported in the format of the International Conference onHarmonisation E3 guideline, a standard that will enable comparisonacross registers and, . . . [Full text of this article]

Ronald Krall, senior vice president, Worldwide Development

GlaxoSmithKline, Upper Merion, PA 19087, USA

Frank Rockhold, senior vice president, Biomedical Data Sciences

frank.w.rockhold@gsk.com GlaxoSmithKline, Upper Merion, PA 19087, USA

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Articles

Next steps in trial registration: Kamran Abbasi and Fiona Godlee
BMJ 2005 330: 1222-1223. [Extract] [Full Text] [PDF]

Compulsory registration of clinical trials: Publicly funded national register of trials would be best in the United Kingdom: Lesley Stewart, Claire Vale, and Janet Darbyshire
BMJ 2004 329: 1043-1044. [Extract] [Full Text]